Esomeprazole Sodium
40 mg · Injection, Powder, Lyophilized, for Solution
- Prescription only
- Proton Pump Inhibitor
- Active substance
- Esomeprazole Sodium
- Made by
- Eugia US LLC
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Esomeprazole Magnesium). It describes the substance, not this exact product.
Esomeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.
Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide.
Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system.
Less than 1% of parent drug is excreted in the urine.
The AUC after administration of a single 40 mg dose of esomeprazole magnesium delayed-release capsules is decreased by 43% to 53% after food intake compared to fasting conditions [see Dosage and Administration ( 2.3 )].
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-20
Safety of the active substance
From the US prescribing label for the same active substance (Esomeprazole Magnesium). It describes the substance, not this exact product.
- Esomeprazole magnesium delayed-release capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation.
- Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6.2 ) ].
- For information about contraindications of amoxicillin and clarithromycin, indicated in combination with esomeprazole magnesium delayed-release capsules for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information.
- Proton pump inhibitors (PPIs), including esomeprazole magnesium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions ( 7 ) ]. · Known hypersensitivity to substituted benzimidazoles or any component of the formulation.
The most frequently occurring adverse reactions (at least 1%) in all three groups were headache (5.5%, 5%, and 3.8%, respectively) and diarrhea (no difference among the three groups).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Bulgaria6 matching products
- Esomeprazole Alupharma 40 mg · powder for solution for injection/infusion
- Esomeprazole Polpharma 40 mg · powder for solution for injection/infusion
- Esomeprazole Rompharm 40 mg · powder for solution for injection/infusion
- Esomeprazole-Tchaikapharma 40 mg · powder for solution for injection/infusion
- Ormus 40 mg · powder for solution for injection/infusion
- Refstop 40 mg · powder for solution for injection/infusion
European UnionNo exact match for this strength and form
Details
| Made by | Eugia US LLC |
|---|---|
| Active substance | Esomeprazole Sodium |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 40 mg |
| Form | Injection, Powder, Lyophilized, for Solution |
| Route | Intravenous |
| Packs | 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL |
| NDC | 55150-185 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.